source
- GSK receives accelerated FDA approval for oral lung cancer drug neladalkibGSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
- CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in studyCG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…